ArticleTissue engineering. Part A2018
Assembly of Tissue-Engineered Blood Vessels with Spatially Controlled Heterogeneities.
Article in Tissue engineering. Part A, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Endothelial Cells Increase Mesenchymal Stem Cell Differentiation in Scaffold-Free 3D Vascular Tissue.Tissue engineering. Part A · 2025Article
- Engineering primitive multiscale chimeric vasculature by combining human microvessels with explanted murine vessels.Scientific reports · 2024Article
- Manufacturing the multiscale vascular hierarchy: progress toward solving the grand challenge of tissue engineering.Trends in biotechnology · 2023Review
- Biofabrication of Collagen Tissue-Engineered Blood Vessels with Direct Co-Axial Extrusion.International journal of molecular sciences · 2022Article
- The Biofabrication of Diseased Artery In Vitro Models.Micromachines · 2022Review
- 3D Tissue-Engineered Vascular Drug Screening Platforms: Promise and Considerations.Frontiers in cardiovascular medicine · 2022Review
- Strategies to counteract adverse remodeling of vascular graft: A 3D view of current graft innovations.Frontiers in bioengineering and biotechnology · 2022Review
- Recent Progress inFrontiers in cardiovascular medicine · 2021Review
- Xenogeneic-free generation of vascular smooth muscle cells from human induced pluripotent stem cells for vascular tissue engineering.Acta biomaterialia · 2021Article
- Extracellular Matrix for Small-Diameter Vascular Grafts.Tissue engineering. Part A · 2020Review
- Disease-inspired tissue engineering: Investigation of cardiovascular pathologies.ACS biomaterials science & engineering · 2020Review
- Building Scaffolds for Tubular Tissue Engineering.Frontiers in bioengineering and biotechnology · 2020Review
- Cryopreservation method for spheroids and fabrication of scaffold-free tubular constructs.PloS one · 2020Article
- A Method for High-Throughput Robotic Assembly of Three-Dimensional Vascular Tissue.Tissue engineering. Part A · 2019Article
- Targeted Delivery of Bioactive Molecules for Vascular Intervention and Tissue Engineering.Frontiers in pharmacology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
Tissue-engineered human blood vessels may enable in vitro disease modeling and drug screening to accelerate advances in vascular medicine. Existing methods for tissue-engineered blood vessel (TEBV) fabrication create homogenous tubes not conducive to modeling the focal pathologies characteristic of certain vascular diseases. We developed a system for generating self-assembled human smooth muscle cell (SMC) ring units, which were fused together into TEBVs. The goal of this study was to assess the feasibility of modular assembly and fusion of ring building units to fabricate spatially controlled, heterogeneous tissue tubes. We first aimed to enhance fusion and reduce total culture time, and determined that reducing ring preculture duration improved tube fusion. Next, we incorporated electrospun polymer ring units onto tube ends as reinforced extensions, which allowed us to cannulate tubes after only 7 days of fusion, and culture tubes with luminal flow in a custom bioreactor. To create focal heterogeneities, we incorporated gelatin microspheres into select ring units during self-assembly, and fused these rings between ring units without microspheres. Cells within rings maintained their spatial position along tissue tubes after fusion. Because tubes fabricated from primary SMCs did not express contractile proteins, we also fabricated tubes from human mesenchymal stem cells, which expressed smooth muscle alpha actin and SM22-α. This work describes a platform approach for creating modular TEBVs with spatially defined structural heterogeneities, which may ultimately be applied to mimic focal diseases such as intimal hyperplasia or aneurysm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.